Rapid Dose Therapeutics provides proprietary oral and non-invasive drug delivery technologies designed for applications of many different types of health products.
VANCOUVER, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) — Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), and Rapid Dose Therapeutics Inc. (“RDT”), a Canadian bio-technology company, which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes, are proud to announce they have signed an additional definitive agreement to bring QuickStrip™ Oral Thin Strips to Puerto Rico. The Company previously announced on October 12, 2018 a definitive agreement to produce QuickStrips™ for the state of California.
Under the terms of the agreement, Chemesis will receive rights to produce, distribute and sell QuickStrip products, with exclusive rights for the cannabis market in Puerto Rico. This partnership allows Chemesis to further strengthen its position in Puerto Rico by allowing the Company to use a convenient drug delivery system that can target a variety of consumers and also allow them to use cannabis products in a new way. The Company will continue to position itself to capitalize in this growing market with innovative and effective products.
“We are pleased to bring RDT and their QuickStrip™ Oral Thin Strips to another growing cannabis market, and we believe this will allow the Company to further increase its market position in Puerto Rico,” said CEO of Chemesis, Edgar Montero. “With RDT recently announcing Aphria as a partner in select global markets, we feel our partnership will add tremendous value to our shareholders.”
“RDT is excited to continue to partner with Chemesis to offer cannabis consumers in Puerto Rico a smoke-free delivery method that is consistent and precise,” explains Mark Upsdell, CEO of RDT. “With Chemesis’ worldwide reach and exclusive partnerships, the QuickStrip™ brand will have the opportunity to establish and grow new markets around the globe.”
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within California.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution, and retail. Chemesis has a facility in California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods, to provide consumers with quality cannabis products.
Chemesis will add shareholder value by exploring opportunities in other emerging markets while consistently delivering quality product to its consumers from seed to sale.
On behalf of the board of directors
CEO and Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release